eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Chemidex Pharma Ltd

Chemidex House, Egham Business Village, Crabtree Road, Egham, Surrey, TW20 8RB
Telephone: +44 (0)1784 477 167
Fax: +44 (0)1784 471 776
WWW: http://www.chemidex.co.uk
Medical Information e-mail: info@chemidex.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 19/01/2009
SPC Haymine Tablets


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

HAYMINE TABLETS


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

Chlorphenamine maleate Ph.Eur. 10 mg

Ephedrine hydrochloride Ph.Eur. 15mg


Go to top of the page
3. PHARMACEUTICAL FORM

Sustained release tablet


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Relief of symptoms caused by allergic conditions such as hay fever, allergic rhinitis, perennial rhinitis, urticaria etc., which are responsive to antihistamine.


Go to top of the page
4.2 Posology and method of administration

Adults, elderly and children over 12 years of age:

One or two tablets daily. One tablet should be taken in the morning on rising and a further tablet may be taken at night if required.

Children under 12 years of age:

Not recommended.

Method of administration - oral use.


Go to top of the page
4.3 Contraindications

Coronary thrombosis, hypertension, thyrotoxicosis and those on treatment with monoamine oxidase inhibitors.


Go to top of the page
4.4 Special warnings and precautions for use

Tablets should be swallowed whole and not sucked or chewed. Do not exceed the stated dose. Asthmatics should consult their doctor before using this product. May cause drowsiness, if affected do not drive or operate machinery. Avoid alcoholic drink.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Alcoholic drinks and certain other central nervous system depressants can potentiate any sedative effect.


Go to top of the page
4.6 Pregnancy and lactation

Contra-indicated.


Go to top of the page
4.7 Effects on ability to drive and use machines

Caution should be employed when driving or operating machinery.


Go to top of the page
4.8 Undesirable effects

Although the combination of ephedrine with the anti-histamine chlorphenamine is intended to reduce side-effects, slight drowsiness may occur. Side effects of ephedrine are rare at the low dose employed in this preparation, however in particularly susceptible patients, effects such as giddiness, palpitations and muscular weakness may be experienced transiently.


Go to top of the page
4.9 Overdose

Treatment should include gastric lavage. In the event of convulsions sedate with intramuscular paraldehyde. Respiratory depression may necessitate mechanical ventilation. Symptomatic treatment of cardiovascular dysfunction should be given with careful patient monitoring. The physician should be aware that tablets in the intestine will continue to release the active ingredients for a period of hours.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Chlorphenamine is a potent H1-blocking drug. It antagonises the pharmacological actions of histamine released by antigen-antibody reaction in allergic diseases, thus providing symptomatic relief. Chlorphenamine alone is less effective when pollen counts are high, allergen exposure is prolonged and nasal congestion has become prominent.

Ephedrine has mild CNS stimulant properties which counteract any drowsiness produced by chlorphenamine. In addition it produces a decongestant action on nasal mucosal surfaces relieving mucosal congestion in conditions such as hay fever and allergic rhinitis.


Go to top of the page
5.2 Pharmacokinetic properties

Chlorphenamine is readily absorbed after oral administration and may undergo enterohepatic re-circulation in man. It is eliminated with a t½ of 12-15 hours.

Ephedrine is completely absorbed following oral administration and is eliminated with a t½ of 3-6 hours.


Go to top of the page
5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Hydroxypropylmethylcellulose

Quinoline yellow

Hardened castor oil

Magnesium stearate

Nipastat


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

4 years


Go to top of the page
6.4 Special precautions for storage

None


Go to top of the page
6.5 Nature and contents of container

Strip packed in soft tempered aluminium foil laminated to polyethylene or blister packed in PVC/polyvinyl dichloride on hard tempered aluminium foil in 10's or 30's in cardboard cartons.


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

CHEMIDEX PHARMA LIMITED

CHEMIDEX HOUSE, EGHAM BUSINESS VILLAGE

CRABTREE ROAD

EGHAM

SURREY

TW20 8RB

UNITED KINGDOM


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 17736/0117


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

9th March 1978 / 22 May 2003


Go to top of the page
10. DATE OF REVISION OF THE TEXT

August 1997



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/21404/SPC/


Active Ingredients/Generics

 
   chlorphenamine maleate
   ephedrine hydrochloride